Sovner R
Habilitative Psychiatry Service, (Department of Psychiatry), New England Medical Center, Boston, MA 02111, USA.
Ment Retard. 1995 Aug;33(4):221-5.
Neuroleptic withdrawal reactions have significant clinical and medicolegal implications for individuals with developmental disabilities. Behavioral deterioration following neuroleptic taper can represent (a) relapse of a mental illness, (b) and anticholinergic rebound reaction, (c) tardive akathisia, and (d) possibly a supersensitivity psychosis. Such reactions may preclude the discontinuation of neuroleptic drug therapy, even in the absence of a drug-responsive psychiatric illness. In this report, the case histories of two individuals who experienced a thioridazine (Mellaril) withdrawal-induced behavioral deterioration were presented. Both reactions were characterized by anxiety and insomnia, and the patients' symptoms were relieved by uncontrolled treatment with clonidine (Catapres) therapy. Evidence for adrenergic hyperactivity as a mediating event was presented.
抗精神病药物撤药反应对发育障碍个体具有重大的临床和法医学意义。抗精神病药物逐渐减量后的行为恶化可能表现为:(a) 精神疾病复发;(b) 抗胆碱能反跳反应;(c) 迟发性静坐不能;以及 (d) 可能是超敏性精神病。即使不存在药物反应性精神疾病,此类反应也可能妨碍抗精神病药物治疗的停药。在本报告中,介绍了两名经历硫利达嗪(美立廉)撤药引起行为恶化的个体的病史。两种反应均以焦虑和失眠为特征,患者的症状通过可乐定(可乐宁)治疗得到缓解。文中提供了肾上腺素能亢进作为中介事件的证据。